“Brazil Genome Map – Precision Medicine in Oncology and Cardiology at SUS”, will create a genetic database of oncology and cardiology patients treated in the Brazilian public health network.
The project, which will contribute to the Program Brazil Genomes launched in 2020 by the Brazilian Government with the aim of encouraging scientific and technological development in the areas of genomics and precision health in the field of SUS, will collect genomic and clinical data from 2,382 oncology and cardiology patients treated at the SUS for the construction of a database.
In addition, genetic research on arterial hypertension will be carried out in 2,000 military policemen, as well as the qualification of 300 professionals who work in public health in Genomics and Precision Medicine.
It is expected that the information compiled by the Genome Map of Brazil contribute to the implementation of population management strategies in breast cancer, colorectal cancer, prostate cancer and cardiovascular diseases.
According to Renato Vieiraexecutive director of Medical, Technical and Education and Research Development, the project will generate more and more knowledge about how pathologies develop and how they behave in the population, contributing to the development of increasingly effective therapies, as well as strategies of prevention.
“Today, when working with genetic sequencing, research or analysis of routine care, professionals rely on databases of the American or European population, but Brazil is a country with continental dimensions and characteristics that vary according to each region. The Map of the Genome of Brazil is a robust proposal that will bring unpublished information on the Brazilian population, directly impacting the care of SUS patients“, explains the specialist and adds that it is proven that “the exponentially growing knowledge of the human genome, combined with solid and well-structured databases, allows medicine to act in a personalized way and highly efficient, both from the point of view of new treatments and individualized prevention for patients at risk. This study, therefore, is a great opportunity for the recognition of genetic factors in the development of Chronic Non-communicable Diseases (NCD) in our population”.
By the end of 2023, genetic material from patients and relatives will be analyzed: 110 for breast cancer, 50 for colorectal cancer and 22 for prostate cancer, located in eight health centers in all regions of the country. Susceptibility to these diseases will be evaluated through the identified variants.
Starting in July 2022, genetic risk stratification for arterial hypertension will be carried out in a group of two thousand military police officers in the city of São Paulo through the implementation of a systemic strategy model to actively track individuals with higher genetic risk. due to pre-existing cardiovascular diseases.
“The results of this study will determine the population genetic risk of these cases, allowing the discovery of new associated biomarkers. As a whole, the information generated will be included in clinical-epidemiological algorithms in use to increase their effectiveness and predictive power. Something necessary for the design of anticipatory strategies for a prevalent disease with high morbidity and mortality”, comments Vieira.
The program of Support for the Institutional Development of the Unified Health System (PROADI-SUS) is a alliance between six reference hospitals in Brazil and the Ministry of Health. Created in 2009, its objective is to support and improve the SUS through human resource training projects, research, evaluation and incorporation of technologies, management and specialized assistance demanded by the Ministry of Health.
The initiative “Brazil Genome Map – Precision Medicine in Oncology and Cardiology at SUS” is led by BP – The Portuguese Beneficence of São Pauloin alliance with the Heart Institute of the Hospital das Clínicas of the Faculty of Medicine of the University of São Paulo (InCor/HCFMUSP).
Please follow and like us: